Skip to main content
. 2014 May;50(100):107–122. doi: 10.1016/j.jaut.2014.01.032

Fig. 3.

Fig. 3

IL-33 induced a subset of IL-10 producing precursor B cells in the blood circulation of WT mice. Peripheral blood cells isolated from WT and IL-10−/− mice at different time points (as indicated in A, B and D; or at 2-weeks in C) after injection with different doses (as indicated, C) or a fixed dose of recombinant hIL-33 (1 μg/mouse, A–B), mIL-33 (0.4 μg/mouse, D), or with PBS only, by procedure described in Fig. 2 legend. The cells were cultured in the presence of PMA/Ionomycin and GolgiStop for 5 h s, and analysed for intracellular IL-10 expression by FACS. A. Selected representative FACS profiles showing intracellular IL-10 expression in B cells (CD19+) isolated from the hIL-33 treated WT C57BL/6 mice (top panels), in comparison with those of similarly treated IL-10−/− control mice (bottom panels). B. Kinetic changes in the frequency of IL-10 producing CD25+ B cells in blood circulation following IL-33 injection. Data shown are mean values calculated from individual mice of each group (n = 4) of one representative experiment. The experiments had been repeated for more than 3 times with consistent results. C & D. Direct comparison of the in vivo effects, potencies and time kinetics of the human versus the mouse IL-33 on B cell activation and IL-10 production. C. Dose-dependent changes in the frequency of CD25-expressing B cells appeared in blood circulation of WT mice following injection of hIL-33 or mIL33 of different dosages as indicated. Data shown are means and standard errors calculated from 3 to 5 mice per group at 2-weeks after the first IL-33 injection. D. Kinetic changes in the frequency of IL-10 producing B cells in blood circulation following injection of hIL-33 (1 μg/inj.) or mIL-33 (0.4 μg/inj.). Values were derived from staining blood samples pooled in equal volumes from 5 individual mice of each group (n = 5), and the experiment has been repeated for at least 5 times with consistent results.